UBS analyst David Dai lowered the firm’s price target on Cullinan Therapeutics (CGEM) to $24 from $30 and keeps a Buy rating on the shares. Cullinan’s key program CLN978 is on track for a data readout in the fourth quarter, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Therapeutics Reports Q1 2025 Financial Results
- Promising Pipeline and Strategic Initiatives Drive Buy Rating for Cullinan Management
- Cullinan Management’s Long-Term Growth Potential: Buy Rating Despite Setbacks
- Cullinan Management’s Strategic Advancements and Financial Stability Justify Buy Rating
- Cullinan Therapeutics reports Q1 EPS (74c), consensus (81c)